CAMBRIDGE, Mass. and BEIJING, China, Aug. 30, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that the company will present at the following upcoming investor conferences:

Baird’s 2017 Global Healthcare Conference
Date: Wednesday, September 6, 2017
Time: 12:15 PM ET
Location: New York, NY

Morgan Stanley 15^th Annual Global Healthcare Conference
Date: Tuesday, September 12, 2017
Time: 3:30 PM ET
Location: New York, NY

Live webcasts of the presentations can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com/. Archived replays will be available for 90 days following the event.

About BeiGene

BeiGene is a global, clinical-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics. With a team of over 400 employees in China, the United States, and Australia, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients.

Investor/Media Contact

Lucy Li, Ph.D.
+1 781-801-1800
ir@beigene.com
media@beigene.com

Source: BeiGene, LTD.